News Home » World » U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead

Around the World

U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead

Randy Mancini 8 November 7, 2022

By Blake Brittain

WASHINGTON (Reuters) – The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co’s Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug.

The justices turned away Juno’s appeal of a lower court’s ruling throwing out the award in the litigation over Kite’s biologic drug Yescarta, in a case that could have repercussions for the cutting-edge biologic drug industry.

(Reporting by Andrew Chung; editing by Grant McCool)

tagreuters.com2022binary_LYNXMPEIA60KY-BASEIMAGE